14 February 2015 | News | By BioSpectrum Bureau
Cipla wins $188.95 Mn of Global Fund ARV Tender
The contract is effective from the 1st of January 2015 and will run for a period of three years
Singapore: The company has been selected as a 'Panel Supplier' for a Supplier Partnership Agreement.
The contract is effective from the 1st of January 2015 and will run for a period of three years. The supplies will begin from Q4 FY 2015.
Mr Subhanu Saxena, MD and global CEO, Cipla, said: "We are extremely proud to have won this tender from Global Fund. Cipla has been committed to the cause of HIV/AIDS for over two decades and this tender offers us a great opportunity to make HIV/AIDS treatment accessible to more than 140 countries through Global Fund."
Cipla has a long-term association with Global Fund, which started in 2002. Last year, the company has been one of the suppliers who has been awarded with a long-term contract for supplying anti-malarial drugs.
The anti-retrovirals drugs will be manufactured in Cipla's state-of-the-art manufacturing facilities in India, which has been approved by various international regulatory agencies.